Genetic or pharmacological inhibition of SOAT1 suppresses cholesterol storage and LD/CE formation, causing an increase in ER cholesterol, which suppresses SREBP-1 activation and reduces fatty acid synthesis, leading to suppression of GBM growth in vitro and in an orthotopic mouse model (Figure 2) [19,20]. The gene discussed is SOAT1; the disease is glioblastoma.